SCHEMBL5751920

SCHEMBL5751920

Cc1c(Oc2ccccc2)c(=O)n(C(C)C)c2nc(Nc3ccc(N4CCN(C)CC4)nc3)ncc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WEE1 P30291 5/20 0.49
EGFR P00533 8/20 0.47
CDK4 P11802 3/20 0.45
CCND1 P24385 3/20 0.45
CCND2 P30279 3/20 0.45
CCND3 P30281 3/20 0.45
CCNB2 O95067 1/20 0.45
CCNE2 O96020 1/20 0.45
CDK1 P06493 1/20 0.45
FGFR1 P11362 1/20 0.45
CCNB1 P14635 1/20 0.45
CCNA2 P20248 1/20 0.45
FGFR2 P21802 1/20 0.45
FGFR4 P22455 1/20 0.45
FGFR3 P22607 1/20 0.45
CCNE1 P24864 1/20 0.45
CDK2 P24941 1/20 0.45
CCNA1 P78396 1/20 0.45
CCNB3 Q8WWL7 1/20 0.45
KDR P35968 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5751188 0.84 FGFR1 (0.51) WEE1EGFRCDK4CCND1CCND2
SCHEMBL5753166 0.75 CDK4 (0.57) WEE1CDK4CCND1CCND2CCND3
SCHEMBL6387070 0.73 CDK4 (0.59) CDK4CCND1CCND2CCND3CCNB2
SCHEMBL5748600 0.72 CDK4 (0.51) CDK4CCND1CCND2CCND3CCNB2
SCHEMBL5753043 0.71 CDK4 (0.61) CDK4CCND1CCND2CCND3CCNB2
SCHEMBL5751631 0.69 CDK4 (0.46) WEE1CDK4CCND1CCND2CCND3
SCHEMBL15391690 0.68 JAK2 (0.64) JAK3JAK2JAK1CYP3A4
SCHEMBL29576526 0.67 WEE1 (0.56) WEE1EGFRCDK4CCND1CCND2
SCHEMBL25156872 0.67 CLK2 (0.47) WEE1EGFRCDK4CCND1CCND2
SCHEMBL30348331 0.67 CLK2 (0.47) WEE1EGFRCDK4CCND1CCND2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1718645-A1 2-(PYRIDIN-3-YLAMINO)-PYRIDO 2,3-D PYRIMIDIN-7-ONES Warner-Lambert Company LLC (US) 2006-11-08 EP claimed
WO-2005082903-A1 2-(PYRIDIN-3-YLAMINO)-PYRIDO[2,3-D]PYRIMIDIN-7-ONES WARNER-LAMBERT COMPANY LLC (US) 2005-09-09 WO claimed
US-20050182078-A1 2-(Pyridin-3-ylamino)-pyrido[2,3-D]pyrimidin-7-ones WARNER-LAMBERT COMPANY, LLC 2005-08-18 US claimed
EP-1718645-A1 2-(PYRIDIN-3-YLAMINO)-PYRIDO 2,3-D PYRIMIDIN-7-ONES Warner-Lambert Company LLC (US) 2006-11-08 EP disclosed
WO-2005082903-A1 2-(PYRIDIN-3-YLAMINO)-PYRIDO[2,3-D]PYRIMIDIN-7-ONES WARNER-LAMBERT COMPANY LLC (US) 2005-09-09 WO disclosed
US-20050182078-A1 2-(Pyridin-3-ylamino)-pyrido[2,3-D]pyrimidin-7-ones WARNER-LAMBERT COMPANY, LLC 2005-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182078-A1 2-(Pyridin-3-ylamino)-pyrido[2,3-D]pyrimidin-7-ones CDK2, CDK4, CDK1 WEE1 168/4885EGFR 914/4885CDK4 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.